7 results about "Fructosamine" patented technology

The invention discloses an application of rhamnolactobacilli SSN-13 in preparation of anti-glycosylation and anti-aging drugs, and is characterized in that the preservation number of the rhamnolactobacilli SSN-13 is CGMCC No: 27227, and the application of the rhamnolactobacilli SSN-13 in preparation of preparations for improving degenerative changes of skin, intestinal tracts, liver and brain tissues and cognitive function decline caused by individual aging is provided, and the application of the rhamnolactobacilli SSN-13 in preparation of anti-glycosylation and anti-aging drugs in preparation of anti-glycosylation and anti-aging drugs in preparation of anti-glycosylation and anti-aging drugs in preparation of anti-glycosylation and anti-aging drugs. According to the present invention, the application in the preparation of the preparation for improving the composition and the structure of the aging individual intestinal flora has the advantages of significantly improving the inhibition ability of glycosylation reaction products AGEs, pentosan, fructosamine and dityrosine, reducing the levels of IL-1beta, IL-6, TNF-alpha, 8-OHdG and AGEs in serum, improving the enzymatic activity of SOD and GSH-Px, improving the HA content and the moisture content in skin, reducing the MDA content, and improving the cognitive ability.

The present invention discloses a multi-item detection integrated machine, which includes an electrochemical detection mechanism, a high pressure liquid chromatography mechanism and a sample adding mechanism, wherein the electrochemical detection mechanism is used to detect the content of blood sugar and fructosamine, and the high pressure liquid chromatography mechanism is used to detect the content of glycosylated hemoglobin; the sample adding mechanism is connected to the high pressure liquid chromatography mechanism, and the sample adding mechanism is used to transport the sample solution to the high pressure liquid chromatography mechanism and drip the sample solution into the electrochemical detection mechanism. In the present invention, by integrating the electrochemical detection mechanism and the high pressure liquid chromatography mechanism, the multi-item detection integrated machine can detect blood sugar, fructosamine and glycosylated hemoglobin at the same time, thereby avoiding the need for three detection items to be performed on three different instrument platforms, improving the detection efficiency, and also avoiding the need for multiple blood draws on patients when detecting different items.

This disclosure relates to a method for evaluating the efficacy of treatment with ranifibranol in patients with liver disease, the method comprising: a) measuring in vitro the levels of a combination of biomarkers consisting of CK18M65, hyaluronic acid, fructosamine, and ALT in a biological sample obtained from a patient; and b) evaluating the efficacy of treatment with ranifibranol according to the levels measured in step a).

The invention provides an extraction composition of camellia oleifera flowers, camellia oleifera shells and camellia oleifera seed shells and application of the extraction composition in anti-aging. The extraction composition comprises the camellia oleifera flower alcohol extract, the camellia oleifera shell alcohol extract and the camellia oleifera seed shell alcohol extract according to the mass ratio of (1-4): (1-4): 1, hyaluronidase can be remarkably inhibited, the excellent anti-aging effect is achieved, generation of initial-stage product fructosamine and final-stage product AGEs of protein non-enzymatic glycosylation can be remarkably inhibited, and the anti-aging effect is good. The whole-process anti-aging effect from early prevention to later repair is realized. In addition, the extracted composition is analyzed by applying a medium effect principle, and the three components in the extracted composition are found to play a synergistic effect in the anti-aging aspect.

The invention relates to the technical field of biological detection, and discloses a glycosylated protein fluid, a preparation method and application thereof and a fructosamine detection kit.The preparation method comprises the following steps that human serum albumin, bovine serum albumin and glucose with the mass ratio being (70-80): (20-30) are added into a buffer solution with the pH ranging from 7.0 to 8.0, incubation is conducted for 14 days to 28 days at the temperature of 36 DEG C to 38 DEG C in a dark place, an obtained reaction solution is purified, and the glycosylated protein fluid is obtained. A glycosylated protein solution is obtained; the ratio of the total protein mass to the glucose mass is 2: 1. The specific proportion of the human serum albumin and the bovine serum albumin can generate a synergistic effect, and an optimal balance is achieved between reduction of a heterologous matrix effect and improvement of stability, so that a calibrator prepared from the glycosylated protein liquid can simultaneously and remarkably improve the correction capability on reagent batch difference and instrument difference. Meanwhile, by controlling the pH value, the temperature and the time and adopting a purification process, the glycosylated protein fluid can have good stability.

The invention discloses a nano enzyme electrode array chip, which is characterized in that three nano enzymes of CuO.Fe2O3, CuO at Fc and NiO at Co are firstly synthesized to respectively realize high-sensitivity and high-stability detection of glucose, fructosamine and lactic acid, and the three nano enzymes can be used as an effective alternative scheme of a traditional enzyme electrode, and then the nano enzyme electrode array chip is prepared based on the three nano enzymes to realize high-sensitivity and high-stability detection of glucose, fructosamine and lactic acid. And in combination with a portable multi-channel electrochemical workstation, synchronous and real-time detection of three diabetes related biomarkers such as glucose, fructosamine and lactic acid in saliva can be realized. The invention also discloses application of the nano-enzyme electrode array chip in multi-element detection of diabetes related biomarkers in saliva.

The disclosure relates to the treatment of blindness due to age-related presbyopia, age-related macular degeneration (AMD), diabetic retinopathy (DR) and / or diabetic macular edema (DME) in a human or animal. Age-related presbyopia is the loss of accommodation in any individual more than 40-50 years old, currently treated by reading glasses. AMD is the most common cause of irreversible loss of sight in persons >65 years in the western world. At this time, no treatment is available for the dry form of AMD. The dry form of AMD is characterized by vision threatening Drüsen, which are (sub)retinal accumulations of advanced glycation end products (AGEs) and fluorophores. DR and DME are the most common cause of irreversible loss of sight in persons <65 years in the western world. Current therapies for age-related presbyopia, AMD, DR and DME are disappointing and do not prevent the evolution to vision impairment, atrophy or blindness. The disclosure specifically relates to the administration of fructosamine-3-kinase and its cofactor(s). This results in deglycation and inactivation of AGEs and fluorophores.